RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

Neuro, Concerning RD-1, one would assume that an interim analysis by the DSMB was done in RD-1, as it was in RD-2. The recent press release said the interim analysis was authorized by the trial protocol, so I assume that would be the case for both trials.

If there had been any procedural problems noted in RD-1 of the type seen in RD-2, wouldn't we have heard about them from Stoll, just as we heard about the delay in RD-2? (that being disclosed as part of the 6-18-08 press release).

Since there was no delay announced in RD-1 of the type that occurred with RD-2, isn't it safe to conclude that there were no procedural problems encountered in RD-1? Thanks.